Opportunities to Improve Symptom Control with Somatostatin Congeners in GEP-NETs: A Review of Key Issues
Oncologist. 2021 Jun 7. doi: 10.1002/onco.13847. Online ahead of print.ABSTRACTOctreotide acetate (octreotide) is the most prescribed and most studied somatostatin congener, or analogue, for gastroenteropancreatic neuroendocrine tumors (GEP-NETs) and carcinoid syndrome, the latter of which may be characterized by debilitating diarrhea and flushing. Approved in the United States more than 30 years ago, octreotide is widely used to control the symptoms of carcinoid syndrome and has been shown to demonstrate anti-proliferative activity. The two formulations available in the United States include a subcutaneous immediate-relea...
Source: The Oncologist - June 7, 2021 Category: Cancer & Oncology Authors: Lowell B Anthony Thomas M O'Dorisio Source Type: research
Opportunities to Improve Symptom Control with Somatostatin Congeners in GEP-NETs: A Review of Key Issues
Oncologist. 2021 Jun 7. doi: 10.1002/onco.13847. Online ahead of print.ABSTRACTOctreotide acetate (octreotide) is the most prescribed and most studied somatostatin congener, or analogue, for gastroenteropancreatic neuroendocrine tumors (GEP-NETs) and carcinoid syndrome, the latter of which may be characterized by debilitating diarrhea and flushing. Approved in the United States more than 30 years ago, octreotide is widely used to control the symptoms of carcinoid syndrome and has been shown to demonstrate anti-proliferative activity. The two formulations available in the United States include a subcutaneous immediate-relea...
Source: The Oncologist - June 7, 2021 Category: Cancer & Oncology Authors: Lowell B Anthony Thomas M O'Dorisio Source Type: research
PPAR-Alpha Agonist Fenofibrate Combined with Octreotide Acetate in the Treatment of Acute Hyperlipidemia Pancreatitis
PPAR Res. 2021 Apr 20;2021:6629455. doi: 10.1155/2021/6629455. eCollection 2021.ABSTRACTAt present, there are more and more patients with acute hypertriglyceridemia pancreatitis in clinical practice. Common treatment measures include fasting and water withdrawal, fluid resuscitation, and somatostatin. In recent years, studies have pointed out that the PPARa agonist fenofibrate may help improve the condition of such patients. Therefore, through clinical research and analysis, we reported for the first time that fenofibrate combined with octreotide acetate has a more excellent effect in the treatment of patients with acute h...
Source: PPAR Research - May 10, 2021 Category: Genetics & Stem Cells Authors: Wen Bao Rui Kong Nan Wang Wei Han Jie Lu Source Type: research
Evaluation of the Octreotide Acetate Pen Injector and its Instructions for Use in a Formative Human Factors Study
ConclusionThe octreotide pen injector and IFU were usable by self-trained participants. Participant errors and suggestions provided a foundation for recommendations to improve the IFU. (Source: Advances in Therapy)
Source: Advances in Therapy - May 4, 2021 Category: Drugs & Pharmacology Source Type: research
Therapeutic effect of presurgical treatment with longacting octreotide (Sandostatin ® LAR®) in patients with acromegaly.
CONCLUSION: We have shown good surgical outcome in patients with acromegaly after pre-treatment with somatostatin analogue, and good tolerance and safety of the therapy, supporting the national recommendation for pre-surgical treatment with long-acting somatostatin analogues in acromegaly patients.
PMID: 32901908 [PubMed - in process] (Source: Endokrynologia Polska)
Source: Endokrynologia Polska - September 11, 2020 Category: Endocrinology Authors: Bolanowski Wrocław M, Zgliczyński W, Sowiński J, Bałdys-Waligórska A, Bednarek-Tupikowska G, Witek P, Zieliński G, Liebert W, Siemińska L, Andrysiak-Mamos E, Marek B, Kajdaniuk D, Malicka J, Rosiek V, Jawiarczyk-Przybyłowska A, Investigators CB Tags: Endokrynol Pol Source Type: research
Ligation and fibrin glue spraying for intractable chylous ascites following radical gastrectomy for gastric cancer: A case report and literature review.
In this report, we discuss a 68-year-old man who underwent distal gastrectomy for early gastric cancer at our hospital who was admitted 8 months after the surgery with a main complaint of abdominal swelling. An abdominal puncture helped to diagnose him with chylous ascites with markedly elevated triglyceride levels. The patient received a hypercaloric infusion through a central line, and octreotide acetate, but without improvement in the patient's condition. After assessment of the lymph outflow using lymph scintigraphy, surgical ligation of the lymph vessels was performed through laparotomy. The volume of the milky-white ...
Source: Journal of Nippon Medical School - August 30, 2020 Category: Universities & Medical Training Authors: Kakinuma D, Kanazawa Y, Matsuno K, Masuda Y, Ando F, Hagiwara N, Fujita I, Nomura T, Yoshiyuki T, Kato S, Yoshida H Tags: J Nippon Med Sch Source Type: research
Evaluation of Nurses ’ and Patients’ Overall Satisfaction with New and Previous Formulations of Octreotide Long-acting Release (Sandostatin LAR ® ): A French Observational Study
ConclusionThe improvement due to the new formulation of Sandostatin LAR® was reported in terms of handling, ease of use and overall nurse satisfaction. The new formulation greatly reduced treatment administration problems associated with the previous formulation, while maintaining low injection site pain and an equivalent safety profile in both indications. (Source: Advances in Therapy)
Source: Advances in Therapy - July 17, 2020 Category: Drugs & Pharmacology Source Type: research
A Retrospective Interventional Cohort Study to Assess the Safety and Efficacy of Sandostatin LAR for Treatment of Recurrent and/or Refractory Meningiomas
Conclusions:This is one of the largest retrospective analysis of meningioma patients treated with Sandostatin LAR (octreotide) suggesting that this treatment has minimal to no adverse events and could prolong overall survival, and progression free survival especially for patients with ER-PR+ tumors who underwent surgeries for small skull-based tumors. (Source: Frontiers in Neurology)
Source: Frontiers in Neurology - May 5, 2020 Category: Neurology Source Type: research
A modified hydrophobic ion-pairing complex strategy for long-term peptide delivery with high drug encapsulation and reduced burst release from PLGA microspheres.
Abstract
Poor encapsulation and high initial burst were two major obstacles for the water-soluble peptide drug loaded microspheres preparation using the industrial emulsification method. In the present study, we hypothesized that the hydrophobic ion-pairing (HIP) complex strategy with a further healing of the pores within the microspheres may improve drug encapsulation and initial burst release. DSS was chosen as the most suitable one among the three test ion-pairing agents (SDS, DSS and STC) due to its high binding efficiency with drug and reversible dissociation capacity in presence of counter ions. The ...
Source: European Journal of Pharmaceutics and Biopharmaceutics - September 25, 2019 Category: Drugs & Pharmacology Authors: Liu J, Xu Y, Liu Z, Ren H, Meng Z, Liu K, Liu Z, Yong J, Wang Y, Li X Tags: Eur J Pharm Biopharm Source Type: research
Development of a novel patient-reported measure for acromegaly: the Acro-TSQ
ConclusionsThe Acro-TSQ is a novel PRO, focused on both disease burden and impact of treatment; it was found to be comprehensive, clear, and relevant for patients with acromegaly receiving injectable SSA treatment. (Source: Pituitary)
Source: Pituitary - September 13, 2019 Category: Endocrinology Source Type: research
